Skip to main content
. Author manuscript; available in PMC: 2013 Feb 1.
Published in final edited form as: Clin Cancer Res. 2011 Dec 5;18(3):869–881. doi: 10.1158/1078-0432.CCR-11-2188

Figure 1. Change in expression of ALDH1A1, CD44 and CD133 from primary to recurrent ovarian cancer.

Figure 1

Figure 1

A) ALDH1A1, CD44 and CD133 expression in 45 high grade ovarian adenocarcinomas was examined using immunohistochemistry. The estimated percentage of positive cells for each sample, with mean (black bars) and median, are shown. B) For all three proteins examined, staining was heterogeneous, rather than diffusely positive. Examples of high and low frequency expression for each are shown (black bar = 100 μm). C) A higher magnification of CD44 and CD133 expression in primary ovarian cancer specimens, demonstrating cell surface expression. D) The average number of positive cells for ALDH1A1, CD44 and CD133 among the 45 primary samples was compared to the average among matched recurrent samples. Only CD133 was significantly higher in recurrent samples. Error bars represent SEM. *P<0.001. E) In order to evaluate the change in each subpopulation for each patient, in addition to the mean of the entire group, the change for each tumor is shown in individual graphs.

HHS Vulnerability Disclosure